Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO4905417 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 20 mg/kg RO4905417 before PCI | EXPERIMENTAL | - |
| 5 mg/kg RO4905417 before PCI | EXPERIMENTAL | - |
| Placebo before PCI | PLACEBO_COMPARATOR | - |
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 10 | PLACEBO_COMPARATOR | - |
| 11 | EXPERIMENTAL | - |
| 12 | PLACEBO_COMPARATOR | - |
| 2 | PLACEBO_COMPARATOR | - |
| 3 | EXPERIMENTAL | - |
| 4 | PLACEBO_COMPARATOR | - |
| 5 | EXPERIMENTAL | - |
| 6 | PLACEBO_COMPARATOR | - |
| 7 | EXPERIMENTAL | - |
| 8 | PLACEBO_COMPARATOR | - |
| 9 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Percutaneous Coronary Intervention (PCI) | PROCEDURE | at least 1 hour and up to 24 hours after completion of drug infusion |
| RO4905417 | DRUG | 5 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI |
| placebo | DRUG | iv infusion, completed at least 1 hour and up to 24 hours before PCI |
Inclusion Criteria: * Adult patients, \>18 to \<75 years of age * Non ST-elevation myocardial infarction * Woman of childbearing potential will be allowed only if using two acceptable methods of contraception * Body mass index (BMI) \</= 40 kg/m2 Exclusion Criteria: * Acute ST-elevation myocardia...
RO4905417 is an investigational small molecule being studied for cardiovascular conditions including coronary heart disease, graft occlusion, peripheral arterial disease (PAD), and myocardial infarction. It has been evaluated in patients undergoing coronary artery bypass graft surgery and in those with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention.
RO4905417 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company has sponsored clinical trials of this investigational drug in cardiovascular indications.
RO4905417 is in Phase 2 clinical development. It has completed Phase 1 and Phase 2 trials, but it remains investigational and has not been approved by regulatory authorities. All reported trials are completed, with no active trials currently listed.
RO4905417 has been studied in three completed trials: NCT00760565, a Phase 1 multiple ascending dose study in healthy volunteers and PAD patients; NCT01245634, a Phase 2 study in patients undergoing CABG surgery; and NCT01327183, a Phase 2 study in non-STEMI patients undergoing PCI. Total enrollment across trials was 532 participants.
No alternative names for RO4905417 have been reported. It is identified solely by its code name RO4905417 in clinical trial registries and available data.